Design and rationale of the VICTORION-Difference study: A phase 4 randomized, double-blind, placebo-controlled clinical trial to assess inclisiran’s early efficacy, safety, tolerability, as well as its impact on quality of life in individuals with hy
Authors
Lawrence Lubyayi (ORCID: https://orcid.org/0000-0001-5286-6488)
Alicia Esteban
Christian Hentschke
Maciej Banach (ORCID: https://orcid.org/0000-0001-6690-6874)
Design and rationale of the VICTORION-Difference study: A phase 4 randomized, double-blind, placebo-controlled clinical trial to assess inclisiran’s early efficacy, safety, tolerability, as well as its impact on quality of life in individuals with hy
Lawrence Lubyayi, Alicia Esteban, Christian Hentschke, Maciej Banach et al.
Citations
1 citations
Journal
American Heart Journal
Topics
Lipoproteins and Cardiovascular Health
Field-Weighted Citation Impact (FWCI)
2.01
article
Design and rationale of the VICTORION-Difference study: A phase 4 randomized, double-blind, placebo-controlled clinical trial to assess inclisiran’s early efficacy, safety, tolerability, as well as its impact on quality of life in individuals with hy
Lawrence Lubyayi, Alicia Esteban, Christian Hentschke, Maciej Banach, Assya Achouba, Ulrike Schatz, Ulrich Laufs, Ephraim B. Winzer, Ulf Landmesser, Bernd Nowak, Ioanna Gouni‐Berthold, Ursula Kassner, A Krueger, Jan Hendrik Streich
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
American Heart JournalVol. 289
Institutions
John Paul II Catholic University of Lublin (PL), Novartis (Switzerland) (CH), Johns Hopkins University (US), University of Cologne (DE), Humboldt-Universität zu Berlin (DE), Novartis (Germany) (DE), Cardiovascular Center Bethanien (DE), Deutsches Herzzentrum der Charité (DE), University Hospital Leipzig (DE), Novartis (United Kingdom) (GB), University Hospital Cologne (DE), University Hospital Carl Gustav Carus (DE), Technische Universität Dresden (DE), Charité - Universitätsmedizin Berlin (DE)